Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead produc…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Avidity Biosciences, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -1.797 | - | 5 | - | -131 | - | -5 | - | -5 | - | 18 |
| 2021 | -2.0300 | -2.726 | 6 | 9 | -43 | -199 | -43 | -9 | -81 | -9 | 13 | 31 |
| 2022 | -2.8300 | -3.356 | 9 | 8 | -117 | -245 | -117 | -8 | -118 | -8 | 26 | 27 |
| 2023 | -3.2400 | -2.648 | 9 | 19 | -169 | -212 | -177 | -19 | -180 | -19 | 37 | 65 |
| 2024 | -2.9100 | -2.867 | 9 | 9 | -212 | -207 | -233 | -9 | -237 | -9 | 54 | 32 |
| 2025 | - | -3.213 | - | 7 | - | -245 | - | -7 | - | -7 | - | 23 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |